Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,724 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hematologic Disease Clear all

Conditions: Hematological Malignancy, Neutropenia
Interventions: Not listed
Lead sponsor: Aaron Cumpston, PharmD, BCOP; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Interventions: Tagraxofusp, Cladribine (CLAD), Cytarabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions: atorvastatin, Tacrolimus, methotrexate; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hemophilia A
Interventions: NXT007, Human Coagulation Factor VIII; Combination Product · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • Iowa City, Iowa

Conditions: Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Infant, Newborn, Diseases
Interventions: Fetoscopic laser surgery; Procedure
Lead sponsor: Assistance Publique - Hôpitaux de Paris; Other
Eligibility: 18 Years and older · Female only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: Aurora, Colorado • Baltimore, Maryland • Cincinnati, Ohio + 5 more

Conditions: Acute Leukemias
Interventions: LDE225; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia, Cervix Neoplasms
Interventions: NESP - Novel Erythropoiesis Stimulating Protein; Drug
Lead sponsor: Mirhashemi, Ramin, M.D.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: pneumococcal polyvalent vaccine, lenalidomide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma, Lymphoid Malignancies
Interventions: ACY-1215; Drug
Lead sponsor: Jennifer Amengual; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Tampa, Florida • New York, New York

Conditions: Acute Myelogenous Leukemia, AML
Interventions: Venetoclax, Cytarabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Leukemia
Interventions: MagProbe (TM); Device
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Blood Sample Collection - Observational Study, Symptom questionnaires - Observational Study; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: imexon; Drug
Lead sponsor: AmpliMed Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Little Rock, Arkansas • Houston, Texas

Conditions: Multiple Myeloma
Interventions: Velcade, Cyclophosphamide, Revlimid; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Lymphoblastic Leukemia
Interventions: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Interventions: Not listed
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 1 Year to 66 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2011
U.S. locations: 191
States / cities: Anchorage, Alaska • Berkeley, California • Burlingame, California + 127 more

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions: genotype-directed dosing with dosing software based on therapeutic drug monitoring; Other
Lead sponsor: The University of Queensland; Other
Eligibility: 2 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions: huCART19-IL18; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Plasma Cell Leukemia
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more

Conditions: Leukemia
Interventions: GM-K562 cell vaccine, Interferon alfa, Sargramostim; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Educational Intervention, Screening Questionnaire Administration, Referral, Questionnaire Administration; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsed Adult AML, Refractory AML
Interventions: Navitoclax Dose Level 1, Navitoclax Dose Level 0, Navitoclax Dose Level 2, Venetoclax Dose Level -1, Venetoclax Dose Levels 0 to 2, Cladribine, Cytarabine (Cladribine Low Dose Cytarabine Backbone), Cytarabine (CLAG-M Backbone), Mitoxantrone, Granulocyte Colony-Stimulating Factor; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Effect of Body Mass on Filgrastim Pharmacokinetics

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia

Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

PRAISE-IR Versus CIBMTR Controls

SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

huCART19-IL18 in CD19+ Cancers

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia